Bondarenko, I. Et Al. 2022. Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation. ANNALS OF ONCOLOGY , vol.33 .

Bondarenko, I., Sezer, A., Kilickap, S., GÜMÜŞ, M., ÖZGÜROĞLU, M., Gogishvili, M., ... He, X.(2022). Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation. ANNALS OF ONCOLOGY , vol.33.

Bondarenko, I. Et Al. "Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation," ANNALS OF ONCOLOGY , vol.33, 2022

Bondarenko, I. Et Al. "Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation." ANNALS OF ONCOLOGY , vol.33, 2022

Bondarenko, I. Et Al. (2022) . "Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation." ANNALS OF ONCOLOGY , vol.33.

@article{article, author={I. Bondarenko Et Al. }, title={Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation}, journal={ANNALS OF ONCOLOGY}, year=2022}